Types and Concentrations of Blood-Based Biomarkers in Adults With Peripheral Neuropathies
A Systematic Review and Meta-analysis

Joel Fundaun, DPT; Melissa Kolski, DPT; Miguel Molina-Álvarez, MSc; Georgios Baskozos, PhD; Annina B. Schmid, PhD, MManipTher

Abstract

IMPORTANCE Peripheral neuropathies are common conditions and can result in numbness, paresthesia, motor deficits, and pain. There is increasing evidence for the use of biomarkers as clinical indicators of the presence, severity, and prognosis of nerve lesions; however, biomarker identification has largely been focused on disorders of the central nervous system, and less is known about their role in the peripheral nervous system.

OBJECTIVE To assess blood-based biomarker concentrations associated with nerve involvement in patients with peripheral neuropathy compared with control participants.

DATA SOURCES Ovid, MEDLINE, Embase, and CINAHL were searched from inception to September 23, 2021.

STUDY SELECTION Observational studies reporting on blood biomarkers in patients diagnosed with peripheral neuropathy were included. This review was preregistered on PROSPERO and followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Data were abstracted by 1 investigator and independently reviewed by a second.

DATA EXTRACTION AND SYNTHESIS Data were meta-analyzed when at least 2 studies reported the same biomarker with comparable methodology. Fixed-effects models were used when only 2 studies were included; random-effects models were used when more than 2 studies were included.

MAIN OUTCOMES AND MEASURES The outcome of interest was concentration of biomarkers.

RESULTS This review included 36 studies reporting on 4414 participants, including 2301 patients with peripheral neuropathy and 2113 controls. Diabetic neuropathy was the most common neuropathy diagnosis (13 studies), followed by Charcot-Marie-Tooth disease (6 studies) and Guillain-Barre syndrome (6 studies). Overall, 16 different blood-based biomarkers associated with nerve involvement were evaluated. The most used were neurofilament light chain, S100B, brain-derived neurotrophic factor, and neuron-specific enolase. Patients with peripheral neuropathy demonstrated significantly higher levels of neurofilament light chain compared with controls (standardized mean difference [SMD], 0.93 [95% CI, 0.82 to 1.05]; P < .001). There were no significant differences in levels of S100B (SMD, 1.10 [95% CI, −3.08 to 5.28]; P = .38), brain-derived neurotrophic factor (SMD, −0.52 [95% CI, −2.23 to 1.19]; P = .40), or neuron-specific enolase (SMD, −0.00 [95% CI, −1.99 to 1.98]; P = .10) in patients with peripheral neuropathy compared with control participants.

Key Points

Question Are peripheral neuropathies associated with altered levels of blood-based biomarkers related to nerve involvement?

Findings This systematic review and meta-analysis included 36 studies reporting on 4414 participants, including 2301 patients with peripheral neuropathy and 2113 controls. Neurofilament light chain was the most commonly reported marker (17 studies) and demonstrated significantly increased serum or plasma concentrations in patients with peripheral neuropathy compared with controls.

Meaning These findings suggest that a blood-based measure of neurofilament light chain may be a useful indicator of neuronal injury in patients with peripheral neuropathy.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.
CONCLUSIONS AND RELEVANCE  The findings of this systematic review and meta-analysis support the use of neurofilament light chain as a blood-based measure associated with the presence of neuronal injury in patients with peripheral neuropathy.

Introduction

Peripheral neuropathies are common conditions, with an estimated prevalence of up to 7% in the general population and an increasing global burden with older age. Patients with peripheral neuropathy often experience significant pain, weakness, and paresthesia that can result in poor balance, limited mobility, increased risk of lower-limb amputation, and shorter mean survival compared with age- and sex-matched controls. The complex clinical presentations of peripheral neuropathies can lead to delayed or missed diagnosis and often have limited treatment strategies.

For central neurological conditions, biomarkers have led to significant advances in the diagnosis, prognosis, and management of numerous conditions, including Alzheimer disease, traumatic brain injury, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). Although biomarker research was initially limited to cerebrospinal fluid (CSF), advanced immunoassays have enabled the identification of blood-based biomarkers. These blood-based assays enable the detection of biomarkers related to the peripheral nervous system. Contrasting the expanding evidence for their efficacy in the central nervous system, the role of biomarkers in peripheral nerve disorders is currently less well understood. Specifically, the identification and role of peripheral nerve biomarkers in peripheral neuropathies remains unclear.

Therefore, the aim of this review was to assess differences in the concentrations of blood-based biomarkers associated with nerve involvement in patients with peripheral neuropathy compared with control participants.

Methods

The reporting of this systematic review and meta-analysis followed the updated Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. This study was preregistered on PROSPERO (CRD42021288101).

Data Sources

We searched Ovid, MEDLINE, Embase, and CINAHL from inception to September 23, 2021, for studies published in English. Search strategies were developed with a medical librarian and are provided in eTable 1 in Supplement 1.

Study Selection

We included observational studies reporting on a quantitative blood-based measure of a biomarker associated with nerve involvement in patients with peripheral neuropathy vs a comparative control group (healthy or comorbid control group without peripheral neuropathy or central nervous system diagnosis). Participants were considered to have peripheral neuropathy if the study reported the use of established diagnostic criteria or confirmed neurological contributions through a clinical neurological examination, electrodiagnostic, or quantitative sensory testing.

Exclusion criteria included: participants younger than 18 years, participants with a concomitant central nervous system disorder, studies without a control group or only including a comorbid control group with neuropathy, studies that did not include biomarkers associated with nerve involvement, data from nonblood biosamples (eg, urine, CSF, saliva), nonquantitative methods to assess...
biomarker concentrations (eg, explorative proteomics or Western blot), and case series, conference abstracts, and randomized clinical trials. When studies met all inclusion criteria but included a mixture of pediatric and adult participants, we contacted the study authors to obtain separate biomarker data for the adult population.

Two reviewers (J.F. and M.M.A.) initially screened study eligibility using titles and abstracts, followed by full texts. Disagreements in selection were resolved by discussion or by mediation of a third reviewer (A.B.S.).

Quality Assessment
Study quality and risk of bias were assessed using the Newcastle-Ottawa Scale (NOS) for observational studies, including cohort, case-control, and cross-sectional study designs. These scales assess selection, comparability, and outcome. Case-control and cohort studies are scored from 0 to 9, with higher scores suggesting lower risk of bias. This score does not include established cutoffs. An adapted NOS for cross-sectional studies was used, which is scored out of 10 and has recommended cutoff scores of 0 to 3 indicating high risk; 4 to 7, moderate risk; and 8 to 10, low risk. Two independent reviewers assessed each study for risk of bias (J.F. and M.K.). Disagreements between reviewers were resolved through consensus or by mediation of a third reviewer (A.B.S.).

Biomarker Selection
Only biomarkers associated with nerve involvement were selected for inclusion and analysis. Biomarkers associated with neuropathy but not directly indicating nerve involvement were excluded (eg, cytokines, chemokines). When the neural relationship of a protein biomarker was unclear, we cross-referenced its physiological function and tissue expression using the Human Protein Atlas. Studies reporting the use of microRNA were screened for neural cell expression using a freely available database reporting expression of animal central nervous system tissue (CNS microRNA profiles; Washington University School of Medicine in St Louis). Neural cell specificity was then cross-referenced with another available RNA database (RNAcentral; European Bioinformatics Institute). We excluded biomarkers whose predominant role and function are outside of the nervous system.

Data Extraction
Data were extracted into a standardized spreadsheet. Extracted data included study and participant characteristics (study design, participant age and sex, timing of sample collection), criteria and duration of peripheral neuropathy diagnosis; analytical platform for biomarker detection (eg, single molecule array, enzyme-linked immunosorbent assay), biomarker concentration for patients and controls, and biomarker diagnostic accuracy (eg, sensitivity, specificity, positive and negative predictive values). When patient populations were compared with multiple control groups, the healthy control group (without disease) was selected as the comparator.

Biomarker concentrations reported as means and SDs were extracted when possible. Per the Cochrane Handbook, alternative summary statistics were transformed to means and SDs using recommended calculations or estimated using Plot Digitizer Software when only reported graphically. Data were extracted by 1 reviewer (J.F.) and independently checked by another reviewer (M.K.). We attempted to contact study authors to obtain any missing or unclear data.

Statistical Analysis
All statistical calculations were performed in R software version 4.0.3 (R Project for Statistical Computing) using the packages meta and metafor. Data were meta-analyzed when at least 2 studies reported on the same biomarker, even if different assays were used. We used a random-effects model with restricted maximum likelihood and inverse variance weighting methods to analyze biomarker data included from more than 2 studies. The Knapp-Hartung adjustment was used to control for the standard error of the pooled effect. A fixed-effect model was used to meta-analyze biomarker data when only 2 studies were included to properly account for between-study
Effect estimates using standardized mean differences (SMDs) and 95% CIs were calculated for biomarker concentrations using Hedges $g$ to correct for bias from small sample sizes. Statistical significance was set at 2-sided $P < .05$. Heterogeneity was calculated using $I^2$ statistics and interpreted as 0% to 40% indicating might not be important; 30% to 60%, moderate; 50% to 90%, substantial; and 75% to 100%, considerable.

Preplanned subgroup meta-analysis according to type of peripheral neuropathy was performed when 2 or more studies analyzed the same biomarker in a similar diagnosis of peripheral neuropathy. Like the primary analysis, overall effect estimates of the concentration of each biomarker were calculated within each subgroup of peripheral neuropathy compared with controls using SMDs and 95% CIs. In individual studies that compared 2 or more subgroups of patients with peripheral neuropathy with 1 control group, the number of control participants was divided by the number of patient subgroups. A post hoc analysis of primarily axonal and demyelinating peripheral neuropathy subtypes was performed as described in the eMethods in Supplement 1.

We also preplanned to meta-analyze diagnostic accuracy data from at least 2 studies using the same biomarker. However, these data were not meta-analyzed, as all included studies reporting diagnostic accuracy data used different diagnostic cutoff thresholds and had high between-study heterogeneity. Results from single studies unable to be meta-analyzed were narratively synthesized using the principles of the Guidance on the Conduct of Narrative Synthesis in Systematic Reviews: A Product from the ESRC Methods Programme.

**Results**

We screened 2216 nonduplicated records, resulting in 36 studies being included after eligibility assessment, including 2301 patients with peripheral neuropathy and 2113 control participants (Figure 1). Participant characteristics are detailed in eTable 2 in Supplement 1. The most commonly reported type of peripheral neuropathy was diabetic neuropathy (13 studies), followed by Charcot-Marie-Tooth disease (6 studies), Guillain-Barre Syndrome (6 studies), chronic inflammatory demyelinating polyneuropathy (5 studies), acute inflammatory demyelinating polyneuropathy (3 studies), and hereditary transthyretin-mediated amyloidosis with polyneuropathy (3 studies). Single studies included hexane-induced neuropathy, critical illness polyneuropathy, acute motor axonal neuropathy, axonal sensorimotor neuropathy, vasculitic neuropathy, rheumatoid arthritis with neuropathy, and leprosy.
with neuropathy, and a cohort including various neuropathies (Table). Data from 3 microRNA biomarker studies were excluded, as the examined markers were not exclusive to the nervous system and involved a diverse range of physiological functions in numerous disease states (e.g., cancer, cardiac disease, immune system disorders).

From all studies, we identified 16 different blood-based biomarkers associated with nerve involvement measured in either serum or plasma. Neurofilament light chain (NFL) was the most studied biomarker (17 studies), followed by 3 studies each for brain-derived neurotrophic factor, S100B, and neuron-specific enolase. Biomarkers from 2 studies included nerve growth factor, neural cellular adhesion molecule, glial fibrillary acidic protein, transmembrane protease serine 5, and neurofilament heavy chain (Table). Biomarkers that were identified from single studies are listed and summarized in eTable 3 in Supplement 1. Study risk of bias from median (range) NOS scores was 6 (2-8) for case-control studies, 8 (5-9) for cross-sectional studies, and 7 (4-9) for cohort studies (eTable 4 in Supplement 1).

**Biomarker Meta-analyses**

Blood-based biomarkers that were significantly increased in patients with peripheral neuropathy compared with control participants included NFL (SMD, 0.93 [95% CI, 0.82 to 1.05]; P < .001; I² = 0%) (Figure 2), neurofilament heavy chain (SMD, 0.41 [95% CI, 0.15 to 0.67]; P = .002; I² = 54%), and transmembrane protease serine 5 (SMD, 1.68 [95% CI, 1.43 to 1.93]; P = .001; I² = 0%), with between-study heterogeneity ranging from not important to moderate (Figure 3). In contrast, nerve growth factor was the only biomarker that showed a significant decrease in patients with peripheral neuropathy compared with controls (SMD, −1.38 [95% CI, −1.68 to −1.09]; P < .001; I² = 98%), with considerable heterogeneity (Figure 3).

Several biomarkers were not significantly different in patients with peripheral neuropathy compared with controls (Figure 4). These included myelin protein zero (SMD, 0.13 [95% CI, −0.24 to 0.50]; P = .50; I² = 99%), S100B (SMD, 1.10 [95% CI, −3.08 to 5.28]; P = .38; I² = 98%), brain-derived neurotrophic factor (SMD, −0.52 [95% CI, −2.23 to 1.19]; P = .40; I² = 95%), glial fibrillary acidic protein (SMD, 0.13 [95% CI, −0.26 to 0.52]; P = .50; I² = 60%), neural cellular adhesion molecule (SMD, 4.09 [95% CI, −0.54 to 8.73]; P = .07; I² = 94%), and neuron-specific enolase (SMD −0.00 [95% CI, −1.99 to 1.98]; P = .10; I² = 94%). All studies had substantial to considerable heterogeneity.

**Diagnostic Subgroup Meta-analyses**

When separately analyzed to detect subgroup differences based on type of peripheral neuropathy (Figure 2, Figure 3, and Figure 4), diabetic neuropathy had increased NFL (SMD, 0.77 [95% CI, 0.42 to 1.13]; P < .001; I² = 0%) and S100B (SMD, 0.93 [95% CI, 0.60 to 1.25]; P < .001; I² = 99%). Nerve growth factor (SMD, −1.38 [95% CI, −1.68 to −1.09]; P < .001; I² = 98%) and brain-derived neurotrophic factor (SMD, −1.49 [95% CI, −1.78 to −1.20]; P < .001; I² = 90%) were decreased. No significant difference was identified in neuron-specific enolase compared with controls (SMD, −0.00 [95% CI, −1.99 to 1.98]; P = .10; I² = 94%) (Table).

In patients with Guillain-Barre syndrome, there was a significant increase in NFL (SMD, 0.79 [95% CI, 0.45 to 1.12]; P = .005; I² = 0%). Similarly, patients with chronic inflammatory demyelinating polyneuropathy had significantly increased NFL (SMD, 0.51 [95% CI, 0.29 to 0.73]; P = .005; I² = 0%). NFL concentrations of predominantly axonal and demyelinating peripheral neuropathy subtypes did not differ (eTable 5 and eFigure 1 in Supplement 1).

Patients with Charcot-Marie-Tooth disease had significantly increased NFL (SMD, 1.11 [95% CI, 0.86 to 1.36]; P < .001; I² = 0%) and transmembrane protease serine 5 (SMD, 1.68 [95% CI, 1.43 to 1.93]; P = .001; I² = 0%) compared with controls. Lastly, patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy had significantly increased levels of NFL (SMD, 0.93 [95% CI, 0.66 to 1.20]; P = .002; I² = 0%) compared with controls.
<table>
<thead>
<tr>
<th>Source</th>
<th>Diagnosis</th>
<th>Control type</th>
<th>Biomarker (blood measure, assay)</th>
<th>Concentration, mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afarideh et al, 2019</td>
<td>Diabetic neuropathy (n = 44)</td>
<td>Healthy (n = 45)</td>
<td>S100B (ELISA)</td>
<td>212.42 (76.79) pg/mL</td>
</tr>
<tr>
<td>Altmann et al, 2020</td>
<td>GBS (n = 27)</td>
<td>Without neuropathy (n = 22)</td>
<td>NFL (SIMOA)</td>
<td>118.9 (141.29) pg/mL</td>
</tr>
<tr>
<td>Azoulay et al, 2020</td>
<td>Diabetic neuropathy (n = 23)</td>
<td>Diabetic without neuropathy (n = 67)</td>
<td>BDNF (ELISA)</td>
<td>14.34 (4.54) ng/mL</td>
</tr>
<tr>
<td>Bischof et al, 2018</td>
<td>Vasculitic neuropathy (n = 11)</td>
<td>Healthy (n = 30)</td>
<td>NFL (SIMOA)</td>
<td>586.91 (784.51) pg/mL</td>
</tr>
<tr>
<td>Celikbilek et al, 2014</td>
<td>Diabetic neuropathy (n = 23)</td>
<td>Diabetic without neuropathy (n = 67)</td>
<td>BDNF (ELISA)</td>
<td>9.79 (4.54) ng/mL</td>
</tr>
<tr>
<td>Ghafouri-Fard et al, 2021</td>
<td>AIDP (n = 22); CIDP (n = 31)</td>
<td>Healthy (n = 49)</td>
<td>BDNF (real-time PCR)</td>
<td>AIDP: −9.77 (1.61) expression levels</td>
</tr>
<tr>
<td>Frithiof et al, 2021</td>
<td>Critical illness polyneuropathy (n = 11)</td>
<td>Critical illness without neuropathy (n = 7)</td>
<td>NFL (SIMOA)</td>
<td>631.43 (545.88) pg/mL</td>
</tr>
<tr>
<td>Hayashi et al, 2021</td>
<td>CIDP (n = 11)</td>
<td>Healthy (n = 7)</td>
<td>NFL (SIMOA)</td>
<td>166.6 (337.8) pg/mL</td>
</tr>
<tr>
<td>Jadhav et al, 2011</td>
<td>Leprosy with neuropathy (n = 48)</td>
<td>Healthy (n = 160)</td>
<td>NFL (plasma, SIMOA)</td>
<td>56.86 (39.6) AU</td>
</tr>
<tr>
<td>Kim et al, 2019</td>
<td>AIDP (n = 14); CIDP (n = 36); AMAN (n = 20); CMT (n = 39)</td>
<td>Healthy (n = 20)</td>
<td>p75 neurotrophin receptor (ELISA)</td>
<td>CIDP: 256 (31.26) pg/mL</td>
</tr>
<tr>
<td>Li et al, 2021</td>
<td>Diabetic neuropathy (n = 56)</td>
<td>Diabetic without neuropathy (n = 24)</td>
<td>GAP-43 (real-time PCR)</td>
<td>0.821 (0.561) expression level</td>
</tr>
<tr>
<td>Li et al, 2013</td>
<td>Diabetic neuropathy (n = 214)</td>
<td>Healthy (n = 136)</td>
<td>NSE (electrochemiluminescence immunoassay automatic analyzer)</td>
<td>10.8 (2.8) ug/L</td>
</tr>
<tr>
<td>Lieverloo et al, 2019</td>
<td>CIDP: induction (n = 29); maintenance (n = 24); remission (n = 27)</td>
<td>Healthy (n = 30)</td>
<td>NFL (SIMOA)</td>
<td>Induction: 47.33 (38.18) pg/mL</td>
</tr>
<tr>
<td>Marietto et al, 2020</td>
<td>Various peripheral neuropathies (n = 37)</td>
<td>Healthy (n = 37)</td>
<td>NFL (SIMOA)</td>
<td>22.93 (21.11) pg/mL</td>
</tr>
<tr>
<td>Martin-Aguilar et al, 2021</td>
<td>GBS (n = 98)</td>
<td>Healthy (n = 53)</td>
<td>NFL (SIMOA)</td>
<td>93.86 (156.28) pg/mL</td>
</tr>
<tr>
<td>Mateos-Hernandez et al, 2016</td>
<td>GBS (n = 8)</td>
<td>Healthy (n = 4)</td>
<td>Piccolo (ELISA)</td>
<td>4.0517 (1.2155) ug/mL</td>
</tr>
<tr>
<td>Millere et al, 2021</td>
<td>CMT (n = 83)</td>
<td>Healthy (n = 56)</td>
<td>NFL (SIMOA)</td>
<td>13.86 (8.81) pg/mL</td>
</tr>
<tr>
<td>Xioaweii et al, 2014</td>
<td>Hexane-induced peripheral neuropathy (n = 18)</td>
<td>Healthy (n = 106)</td>
<td>Human myelin protein P0 (ELISA)</td>
<td>407.21 (93.60) pg/mL</td>
</tr>
</tbody>
</table>

(continued)
Table. Study Characteristics, Including Type of Neuropathy and Concentrations of Blood Biomarkers (continued)

<table>
<thead>
<tr>
<th>Source</th>
<th>Diagnosis</th>
<th>Control type</th>
<th>Biomarker (blood measure, assay)</th>
<th>Concentration, mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Patient</td>
<td>Control</td>
<td></td>
</tr>
<tr>
<td>Niezgoda et al,26 2017</td>
<td>Demyelinating polyneuropathy (n = 80); axonal polyneuropathy (n = 40); diabetic polyneuropathy (n = 20)</td>
<td>Healthy (n = 20)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neural cellular adhesion molecule (serum, ELISA)</td>
<td>Demyelinating: 4588.7 (1763.6) ng/mL</td>
<td>Axonal: 3138.4 (1221.3) ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Diabetic: 2869.7 (923.5) ng/mL</td>
<td></td>
</tr>
<tr>
<td>Ozuguz et al,27 2016</td>
<td>Diabetic neuropathy (n = 26)</td>
<td>Nonneurological disease (n = 70)</td>
<td>Nerve growth factor (serum, ELISA)</td>
<td>13.1 (2.6) pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rossor et al,36 2016</td>
<td>CMT (n = 90)</td>
<td>Healthy (n = 79)</td>
<td>Neurofilament heavy chain (plasma, ELISA)</td>
<td>27.4 (22.0) ng/mL</td>
</tr>
<tr>
<td>Maia et al,49 2020</td>
<td>Hereditary transthyretin-mediated amyloidosis with polyneuropathy, group 1 (n = 18); group 2 (n = 26)</td>
<td>Healthy (n = 16)</td>
<td>NFL (plasma, SIMOA) Group 1: 29.34 (47.37) pg/mL</td>
<td>5.57 (4.44) pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Group 2: 117.06 (98.18) pg/mL</td>
<td></td>
</tr>
<tr>
<td>Salih et al,54 2000</td>
<td>Rheumatoid arthritis with peripheral neuropathy (n = 28)</td>
<td>Healthy (n = 28)</td>
<td>Antineuroblastoma cell antibodies (serum, ELISA) IgG: 4.86 (2.76) AU</td>
<td>IgM: 1.85 (2.49) AU</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IgM: 2.29 (1.58) AU</td>
</tr>
<tr>
<td>Sandelius et al,37 2018</td>
<td>CMT (n = 75)</td>
<td>Healthy (n = 67)</td>
<td>NFL (plasma, SIMOA)</td>
<td>25.63 (12.07) pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sandhu et al,28 2008</td>
<td>Diabetic neuropathy (n = 24)</td>
<td>Healthy (n = 26)</td>
<td>NSE (whole blood, PCR) 0.0067 (0.0038) expression level</td>
<td>0.0094 (0.0048) expression level</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qiao et al,29 2015</td>
<td>Diabetic neuropathy (n = 23)</td>
<td>Nonneurological disease (n = 62)</td>
<td>Neurofilament heavy chain (serum, ELISA)</td>
<td>739.98 (791.28) pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sessa et al,41 1997</td>
<td>GBS (n = 61)</td>
<td>Healthy (n = 40)</td>
<td>Myelin-associated β4 integrin (serum, ELISA)</td>
<td>0.208 (0.606)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sun et al,30 2018</td>
<td>Diabetic neuropathy (n = 65)</td>
<td>Healthy (n = 110)</td>
<td>Nerve growth factor (serum, ELISA) BDNF (serum, ELISA)</td>
<td>42.7(4.9) pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1739.8 (132.9) pg/mL</td>
</tr>
<tr>
<td>Ticau et al,31 2021</td>
<td>Hereditary transthyretin-mediated amyloidosis with polyneuropathy (n = 159)</td>
<td>Healthy (n = 57)</td>
<td>NFL (plasma, SIMOA)</td>
<td>69.43 (60.50) pg/mL</td>
</tr>
<tr>
<td>Wang et al,19 2020</td>
<td>CMT: group 1 (n = 20); group 2 (n = 31)</td>
<td>Healthy: group 1 (n = 20); group 2 (n = 24)</td>
<td>TPMRSS5 (plasma, immuno-PCR, SIMOA) NPX: group 1: 4.37 (0.62)*</td>
<td>NPX control 1: 3.32 (0.50)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group 2: 4.42 (0.49)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NPX: group 1: 3.60 (0.38)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group 2: 3.52 (0.76)*</td>
</tr>
<tr>
<td>Wang et al,19 2021</td>
<td>CMT, TMPRSS5 (n = 65); NFL (n = 41)</td>
<td>Healthy, TMPRSS5 (n = 52); NFL (n = 40)</td>
<td>TPMRSS5 (plasma, immuno-PCR, SIMOA) NPX: 4.63 (0.74)*</td>
<td>NPX: 3.57 (0.52)*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NPX: 3.5 (0.60)*</td>
</tr>
<tr>
<td>Ziegler et al,31 2019</td>
<td>Diabetic neuropathy (n = 304)</td>
<td>Healthy (n = 354)</td>
<td>Neurotrophin-3 (serum, inflammation multiplex immunosassay) NPX: 0.87 (0.40)</td>
<td>NPX: 1.03 (0.34)</td>
</tr>
<tr>
<td>Morgenstern et al,32 2021</td>
<td>Diabetic neuropathy (n = 63)</td>
<td>Healthy (n = 30)</td>
<td>NFL (serum, SIMOA) Myelin protein zero (serum, SIMOA)</td>
<td>14.69 (8.5) pg/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.189 (2.528) expression levels mRNA</td>
</tr>
<tr>
<td>Celikbiyik et al,33 2014</td>
<td>Prediabetic neuropathy (n = 22)</td>
<td>Healthy (n = 30)</td>
<td>NFL (serum, real-time PCR) NSE (serum, real-time PCR)</td>
<td>0.0163 (0.0158) mRNA expression*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NSE: 0.209 (0.078) mRNA expression*</td>
</tr>
</tbody>
</table>

Abbreviations: AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; AU, arbitrary units; BDNF, brain-derived neurotrophic factors; CIDP, chronic inflammatory demyelinating polyneuropathy; CMT, Charcot-Marie-Tooth disease; ELISA, enzyme-linked immunosorbent assay; GAP-43, growth association protein 43; GFAP, glial fibrillary acidic protein; GBS, Guillain-Barre syndrome; Ig, immunoglobulin; NCAM, neural cell adhesion molecule; NFL, neurofilament light chain; NSE, neuron-specific enolase; NPX, normalized protein expression; PCR, polymerase chain reaction; SIMOA, single molecule array, TPMRSS5, transmembrane protease serine 5.

* Indicates data were estimated from graphs or figures.

Diagnostic Accuracy

Meta-analyses of biomarker diagnostic accuracy could not be performed due to significant differences in concentration cutoff values among studies (eg, NFL range, 8.9 to 155 pg/mL) and varying peripheral neuropathy diagnoses. Biomarker concentration cutoff values and corresponding diagnostic accuracy data are listed in eTable 6 in Supplement 1.
Discussion

Our systematic review and meta-analysis identified 16 blood-based biomarkers from 36 studies, including 2301 patients with peripheral neuropathy and 2113 control participants. Our meta-analyses identified 4 biomarkers that were significantly altered in patients with peripheral neuropathy compared with controls. Among those, NFL was consistently upregulated in peripheral neuropathy with a large effect size (based on 17 studies32,33,35,37,41,43,46-50,52,53,56 and 8 types of neuropathies). Neurofilament heavy chain, transmembrane protease serine 5, and nerve growth factor were also significantly dysregulated, with magnitudes of effect size ranging from moderate to large. However, these results were derived from only 2 studies with higher heterogeneity.

Association of NFL With Peripheral Neuropathies

Our findings from 854 patients with peripheral neuropathy and 561 controls strongly suggest that a blood-based measure of NFL was a useful biomarker in patients with peripheral neuropathy. Increased concentrations of NFL were consistently identified in each type of peripheral neuropathy.

![Figure 2. Meta-analysis of Neurofilament Light Chain in Patients With Peripheral Neuropathy Compared With Controls](image-url)

Table 1 summarizes and further subgrouped based on the type of peripheral neuropathy.
using varying methods of blood collection (eg, plasma, serum) and immunoassays (eg, enzyme-linked immunosorbent assay, single molecule array). These findings in peripheral neuropathies are aligned with strong evidence demonstrating increased concentrations of NFL in several central nervous system conditions, including ALS, Alzheimer Disease, multiple sclerosis, and traumatic brain injury. NFL’s functional role in axonal growth and stability and its high expression in neuronal tissue make it a robust neuronal biomarker. Our data corroborate using NFL as a blood-based biomarker not only for central but also for peripheral neuropathies.

**Associations of Additional Biomarkers With Peripheral Neuropathies**

Our meta-analyses highlighted additional biomarkers that may be useful in peripheral neuropathies. Neurofilament heavy chain, transmembrane protein serine 5, and nerve growth factor were significantly altered in patients with peripheral neuropathy compared with controls. Biomarkers that were not significantly altered (eg, brain-derived neurotrophic factor, glial fibrillary acidic protein, neural cellular adhesion molecule) may be more limited as blood-based measures of nerve involvement due to their diverse neurological functions. However, firm conclusions regarding the use of these biomarkers cannot be drawn, as all meta-analyses (except NFL) were taken from a small number of studies with significant between-study heterogeneity. Further research is needed to understand the role of these biomarkers in the context of different types of peripheral neuropathies.
Figure 4. Meta-analyses of Blood-Based Biomarkers That Did Not Demonstrate a Statistically Significant Difference of Concentrations in Patients With Peripheral Neuropathy Compared With Controls

A. Glial fibrillary acidic protein

<table>
<thead>
<tr>
<th>Source</th>
<th>SMD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Critical illness neuropathy</td>
<td>-0.87 (-1.13 to 0.17)</td>
</tr>
<tr>
<td>Diabetic neuropathy</td>
<td>-0.61 (-1.18 to 0.04)</td>
</tr>
<tr>
<td>Total (fixed effect)</td>
<td>0.13 (-0.26 to 0.52)</td>
</tr>
</tbody>
</table>

Heterogeneity: χ² = 2.47 (P = 0.12); I² = 60%

B. Neuron-specific enolase

<table>
<thead>
<tr>
<th>Source</th>
<th>SMD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic neuropathy</td>
<td>0.86 (0.64 to 1.09)</td>
</tr>
<tr>
<td>Sandhu et al, 2008</td>
<td>-0.36 (-0.91 to 0.20)</td>
</tr>
<tr>
<td>Total (random effects)</td>
<td>0.00 (-1.99 to 1.98)</td>
</tr>
</tbody>
</table>

Heterogeneity: χ² = 33.63 (P < .001); I² = 94%

C. Myelin protein zero

<table>
<thead>
<tr>
<th>Source</th>
<th>SMD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic neuropathy</td>
<td>-1.37 (-1.85 to -0.89)</td>
</tr>
<tr>
<td>Hexane-induced neuropathy</td>
<td>2.32 (1.74 to 2.90)</td>
</tr>
<tr>
<td>Total (fixed effect)</td>
<td>0.13 (-0.24 to 0.50)</td>
</tr>
</tbody>
</table>

Heterogeneity: χ² = 92.56 (P < .001); I² = 99%

D. S100B

<table>
<thead>
<tr>
<th>Source</th>
<th>SMD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic neuropathy</td>
<td>2.87 (2.36 to 3.38)</td>
</tr>
<tr>
<td>Gefil et al, 2014</td>
<td>0.09 (0.59 to 1.26)</td>
</tr>
<tr>
<td>Total (random effects)</td>
<td>0.93 (0.60 to 1.25)</td>
</tr>
</tbody>
</table>

Heterogeneity: χ² = 98.03 (P < .001); I² = 98%

E. Neural cellular adhesion molecule

<table>
<thead>
<tr>
<th>Source</th>
<th>SMD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic inflammatory demyelinating polyneuropathy</td>
<td>5.66 (4.07 to 7.25)</td>
</tr>
<tr>
<td>Acute inflammatory demyelinating polyneuropathy</td>
<td>3.89 (2.18 to 5.61)</td>
</tr>
<tr>
<td>Acute motor axonal neuropathy</td>
<td>0.38 (-0.61 to 1.36)</td>
</tr>
</tbody>
</table>

Heterogeneity: χ² = 95.09 (P < .001); I² = 94%

F. Brain derived neurotrophic factor

<table>
<thead>
<tr>
<th>Source</th>
<th>SMD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic neuropathy</td>
<td>-0.86 (-1.36 to -0.37)</td>
</tr>
<tr>
<td>Sun et al, 2018</td>
<td>-1.83 (-2.20 to -1.47)</td>
</tr>
<tr>
<td>Total (fixed effect)</td>
<td>-1.49 (-1.78 to -1.20)</td>
</tr>
</tbody>
</table>

Heterogeneity: χ² = 65.45 (P < .001); I² = 94%

Overall effect sizes, standardized mean differences (SMDs), 95% CIs, and heterogeneity (I²) are summarized for each biomarker and further subgrouped based on the type of peripheral neuropathy. The scales for standardized mean differences vary by biomarker.
Potential Clinical Implications and Considerations for Future Research

Early Detection
There is growing evidence for the use of biomarkers in the early detection of nerve involvement. Numerous studies have shown that NFL is a reliable measure of nerve involvement in the presymptomatic stage of central nervous system diseases, including frontotemporal dementia, Alzheimer disease, multiple sclerosis, and ALS. To date, the role of blood biomarkers for the early or presymptomatic detection of peripheral neuropathy remains understudied. We only identified 1 such study assessing potential early signs of neuropathy in patients with prediabetes. This study identified increased expression of NFL in patients with prediabetes compared with healthy controls. Therefore, more studies are needed to understand biomarkers' ability to detect presymptomatic pathology.

Diagnosis
Patients with peripheral neuropathy often have comorbid conditions (eg, cardiovascular, immune, or metabolic dysfunction) making it difficult to detect and diagnose neuropathy. For example, it is currently estimated that physicians only recognize neuropathy symptoms in less than one-third of patients presenting with symptomatic diabetic neuropathy, supporting the need for improved diagnostic tools. Initial CSF-based diagnostic studies using NFL highlighted its discriminatory ability in multiple neurological conditions. Advanced immunoassays can now reliably detect lower concentrations of NFL in the blood and strongly correlate with CSF concentrations. Similarly, a 2021 study using plasma NFL confirmed significant diagnostic implications in multiple neurodegenerative conditions. Although study heterogeneity limited our ability to meta-analyze diagnostic cutoff thresholds, numerous studies in our systematic review demonstrated strong diagnostic accuracy. This included using NFL to discriminate between patients with and without vasculitic neuropathy, symptomatic vs asymptomatic hereditary transthyretin-mediated amyloidosis with polyneuropathy, and between patients with Charcot-Marie-Tooth disease and healthy controls. Future research considering the optimal type of blood analysis and immunological assay is needed to develop generally accepted clinical diagnostic cutoffs for patients with different types of peripheral neuropathy. Of note, NFL did not seem to be a good marker to differentiate primarily axonal from demyelinating types of neuropathies with elevated levels in both types.

Prognosis
Biomarkers could serve important roles in evaluating the severity and prognosis of peripheral neuropathies. Although meta-analyzing this was out of scope for this review, several included studies showed a significant association between NFL and disease severity, including Charcot-Marie-Tooth disease and Guillain-Barre Syndrome. Additionally, 2 studies in patients with diabetic neuropathy identified significant associations between increased NFL concentrations and neuropathic pain, as well as a hyperalgesic pain phenotype. Although few studies included long-term follow-up data, 1 study in Guillain-Barre syndrome highlighted NFL's ability to estimate patients' ability to walk or run independently 1 year after disease onset.

Treatment Stratification
Biomarkers may also be used to improve treatment through patient stratification. The pathophysiology of neuropathies is diverse and requires unique, individualized treatments. Identifying robust clinical biomarkers could lead to improved quality and cost-effectiveness of care. Further development and validation is currently required before biomarkers can be used for patient stratification in clinical neurology. The identification of promising biomarker candidates in this review provides an important initial step to progress toward personalized management for people with peripheral neuropathies.
Limitations

There are limitations to consider when interpreting our results. First, publication bias may prevent the reporting of negative results of biomarker data. Additionally, only English-language publications were included and between-study heterogeneity in smaller studies (eg, methodological heterogeneity) may limit the generalizability of our findings. The overall quality of included studies was high. Limited reporting or adjustment of confounding variables between participants and controls was the primary limitation, which was only identified in 5 of 36 studies. Furthermore, it is important to consider the pathophysiological differences in peripheral neuropathies. This needs to be remembered when interpreting the overall meta-analyses of certain biomarkers, as some markers may be more useful in certain neuropathies than others.

Conclusions

In this systematic review and meta-analysis, our findings supported the use of NFL as a blood-based biomarker of nerve involvement in patients with peripheral neuropathy. When compared with other nerve-related biomarkers, NFL was consistently increased in patients with varying types of peripheral neuropathies compared with control participants. Neurofilament heavy chain, transmembrane protease serine 5, and nerve growth factor were also significantly altered in peripheral neuropathy, although these results are based on few studies. Future research is required to assess the temporal patterns, diagnostic accuracy, and prognostic ability of these biomarkers in patients with peripheral neuropathy and peripheral nerve injuries.

ARTICLE INFORMATION

Accepted for Publication: November 9, 2022.
Published: December 27, 2022. doi:10.1001/jamanetworkopen.2022.48593
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Fundaun J et al. JAMA Network Open.

Corresponding Author: Annina B. Schmid, PhD, MMManipTher, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, West Wing Level 6, OX3 9DU Oxford, United Kingdom (annina.schmid@neuro-research.ch).

Author Affiliations: Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom (Fundaun, Baskozos, Schmid); Department of Physical Therapy and Human Movement Sciences, Northwestern University, Feinberg School of Medicine, Chicago, Illinois (Kolski); Musculoskeletal Outpatient Department, Shirley Ryan AbilityLab, Chicago, Illinois (Kolski); Area of Pharmacology, Nutrition, and Bromatology, Department of Basic Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain (Molina-Álvarez).

Author Contributions: Drs Fundaun and Schmid had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Baskozos and Schmid contributed equally.

Concept and design: Fundaun, Kolski, Baskozos, Schmid.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Fundaun, Kolski, Molina Álvarez, Schmid.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Fundaun, Molina Álvarez, Baskozos, Schmid.
Obtained funding: Schmid.
Administrative, technical, or material support: Fundaun, Kolski, Molina Álvarez.
Supervision: Baskozos, Schmid.

Conflict of Interest Disclosures: Dr Baskozos reported receiving grants from the Medical Research Council (MRC) and Versus Arthritis outside the submitted work. Dr Schmid reported receiving grants from Ono Pharmaceutical and UK Research and Innovation outside the submitted work. No other disclosures were reported.


Downloaded From: https://jamanetwork.com/ on 12/29/2022
Funding/Support: Dr Fundaun is supported by a Versus Arthritis Pain Challenge Grant. Dr Schmid is supported by a Wellcome Trust Clinical Research Career Development Fellowship (award No. 222101/Z/20/Z) and the Medical Research Foundation (Emerging Leaders Prize in Pain Research, grant No. MRF-160-003-ELP-SCHM-C0842). The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. Dr Baskozos is funded by Diabetes UK (grant No. 19/0005984), MRC, and Versus Arthritis through the PAINSTORM consortium and FORECAST study as part of the Advanced Pain Discovery Platform (grants No. MR/W023881/1 and MR/W027003/1) and by the Wellcome Trust (grant No. 223149/Z/21/Z).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the UK Department of Health.

Data Sharing Statement: See Supplement 2.

Additional Contributions: Neal Thurley, MA (University of Oxford Bodleian Health Care Libraries), assisted in developing our search strategy. He was not compensated for this work.

REFERENCES

See Supplement 2.


**SUPPLEMENT 1.**

eTable 1. Search Strategies for All Included Search Engines
eMethods. Data Extraction and Subtype Selection for Primarily Axonal and Demyelinating Peripheral Neuropathy
eTable 2. Summary of Diagnostic Criteria and Cohort Characteristics at Study-Level
eTable 3. Summary of Biomarker Results Reported in Single Studies
eTable 4. Quality Assessment Using the Newcastle-Ottawa Scales
eTable 5. Diagnostic Criteria and Neurofilament Light Chain Concentrations Used in the Subgroup Meta-analysis Comparing Primarily Axonal vs Demyelinating Peripheral Neuropathies
eTable 6. Descriptive Synthesis of Biomarker Diagnostic Accuracy
eFigure 1. Meta-analysis of Neurofilament Light Chain Comparing Axonal and Demyelinating Subtypes in Patients With Peripheral Neuropathy Compared With Controls
eFigure 2. Bulk Tissue Gene Expression Profile for Neurofilament Light Chain According to GTEx Portal

**SUPPLEMENT 2.**

Data Sharing Statement